{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:59:54Z","timestamp":1791500394409,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":2625,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1093\/annonc\/mds228","type":"journal-article","created":{"date-parts":[[2012,9,20]],"date-time":"2012-09-20T03:42:47Z","timestamp":1348112567000},"page":"vii72-vii77","source":"Crossref","is-referenced-by-count":80,"special_numbering":"S7","title":["Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"23","author":[{"given":"M.","family":"Baccarani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds228_bb0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"European LeukemiaNet. Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds228_bb0015","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds228_bb0020","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0025","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds228_bb0030","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(07)70379-0","article-title":"Part II: management of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds228_bb0035","series-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues","first-page":"32","article-title":"Chronic myelogenous leukemia, BCR-ABL1 positive","author":"Vardiman","year":"2008"},{"key":"10.1093\/annonc\/mds228_bb0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u2018good-risk\u2019 chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0045","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds228_bb0050","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0055","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0060","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds228_bb0065","first-page":"94","article-title":"Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use","volume":"29","author":"Hook","year":"1977","journal-title":"Am J Hum Genet"},{"key":"10.1093\/annonc\/mds228_bb0070","series-title":"ISCN 2009. An International System for Human Cytogenetic","author":"Shaffer","year":"2009"},{"key":"10.1093\/annonc\/mds228_bb0075","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0085","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0090","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds228_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0037-1963(03)70040-7","article-title":"Interferon-alfa for chronic myeloid leukemia","volume":"40","author":"Baccarani","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1093\/annonc\/mds228_bb0100","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds228_bb0105","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds228_bb0110","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds228_bb0115","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds228_bb0120","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0125","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds228_bb0130","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0135","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0140","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0145","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds228_bb0150","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds228_bb0155","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0160","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Superiority of nilotinib versus imatinib for the treatment of patients newly diagnosed chronich phase Ph+ chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomized ENESTnd study","volume":"12","author":"Kantarijan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds228_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mds228_bb0170","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds228_bb0175","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0180","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","article-title":"Three decades of transplantation for chronic myeloid leukemia: what have we learned?","volume":"117","author":"Pavlu","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0185","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","article-title":"Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia","volume":"104","author":"Baccarani","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0190","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds228_bb0195","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low-or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds228_bb0200","article-title":"Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia\u2013BELA trial: 24-month follow-up","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mds228_bb0205","article-title":"Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mds228_bb0210","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419376586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419376586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/suppl_7\/vii72\/6674453\/mds228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:14:11Z","timestamp":1582179251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419376586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":41,"alternative-id":["S0923753419376586"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds228","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}